A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS)
Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT. Bronchiolitis obliter... (Source: Trials)
Source: Trials - April 6, 2024 Category: General Medicine Authors: Naeemeh Dini, Amin Pastaki Khoshbin, Rasoul Aliannejad, Hooman Bakhshandeh, Katayoun Najafizadeh, Mahshid Mehdizadeh and Shahideh Amini Tags: Study protocol Source Type: research
Clinical Efficacy Observation of Acetylcysteine Combined with Tiotropium Bromide Inhalation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
(Source: Journal of Biomedical Nanotechnology)
Source: Journal of Biomedical Nanotechnology - March 27, 2024 Category: Nanotechnology Authors: Yuan, Lei Tags: research-article Source Type: research
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020 –2023
ConclusionOur study suggests that inhaled LAMAs are not free from cardiac AE risks. This risk may be more evident when the newer LAMAs are used, but it is generally significantly reduced when COPD patients are treated with dual bronchodilators or triple therapy. However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug ’s safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue. (Source: Lung)
Source: Lung - February 6, 2024 Category: Respiratory Medicine Source Type: research
Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (iBCS)
Eur J Pharm Biopharm. 2024 Feb 3:114206. doi: 10.1016/j.ejpb.2024.114206. Online ahead of print.ABSTRACTAn inhalation-based Biopharmaceutical Classification System for pulmonary drugs (iBCS) holds the perspective to allow for scientifically sound prediction of differences in the in vivo performance of orally inhaled drug products (OIDPs). A set of nine drug substances were selected, that are administered via both the oral and pulmonary routes. Their solubility was determined in media representative for the oral (Fasted State Simulated Intestinal Fluid (FaSSIF)) and pulmonary (Alveofact medium and Simulated Lung Fluid (SLF)...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 5, 2024 Category: Drugs & Pharmacology Authors: Andreea Floroiu Brigitta Loretz Johannes Kr ämer Claus-Michael Lehr Source Type: research
Cost-utility of tiotropium in patients with severe asthma
Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country. (Source: Cost Effectiveness and Resource Allocation)
Source: Cost Effectiveness and Resource Allocation - January 18, 2024 Category: Health Management Authors: Jefferson Antonio Buend ía and Diana Guerrero Patiño Tags: Research Source Type: research
Tiotropium reduces clinically important deterioration in patients with mild-to-moderate chronic obstructive pulmonary disease: A post hoc analysis of the Tie-COPD study
Clinically important deterioration (CID) is a composite endpoint used to holistically assess the complex progression of chronic obstructive pulmonary disease (COPD). Tiotropium improves lung function and reduces the rate of COPD exacerbations in patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate). However, whether tiotropium reduces CID risk in patients with mild-to-moderate COPD remains unclear. (Source: Respiratory Medicine)
Source: Respiratory Medicine - January 8, 2024 Category: Respiratory Medicine Authors: Fan Wu, Cuiqiong Dai, Yumin Zhou, Zhishan Deng, Zihui Wang, Xiaochen Li, Shuyun Chen, Weijie Guan, Nanshan Zhong, Pixin Ran Tags: Original Research Source Type: research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
CONCLUSIONS: Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.PMID:38116664 | DOI:10.1080/14737167.2023.2296561 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 20, 2023 Category: Health Management Authors: Katrina S Firlik Vamshi Ruthwik Anupindi Vincent Hayes Mitchell DeKoven Asif Shaikh Jessica Franchino-Elder Source Type: research
EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective
This analysis assessed the cost-effectiveness of umeclidinium/vilanterol (UMEC/VI) versus tiotropium/olodaterol (TIO/OLO) for the treatment of chronic obstructive pulmonary disease (COPD), from a United Kingdom (UK) National Healthcare System perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Kendall, A. Martin, D. Shah, S.G. Noorduyn, P. Dasari, N. Risebrough, A. Ismaila Source Type: research
Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis
ConclusionADE signals were generated for several potential GPx1 inhibitors; however, further validation of signals is required in large well-controlled observational studies. (Source: Drug Safety)
Source: Drug Safety - November 23, 2023 Category: Drugs & Pharmacology Source Type: research
Dynamic chest radiography evaluation of the effects of tiotropium/olodaterol combination therapy in COPD: EMBODY study protocol
Conclusions: The EMBODY study is the first to evaluate the effects of bronchodilator therapy on the respiratory kinetics in COPD using DCR. The study could provide additional evidence of the potential of DCR for evaluating COPD therapy. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Ikari, J., Katsumata, M., Imamoto, T., Suzuki, Y., Nishiyama, A., Yokota, H., Ozawa, Y., Suzuki, E., Kawata, N., Sakao, S., Tatsumi, K., Suzuki, T. Tags: Imaging Source Type: research
Interpreting the significance of collagen-IV level changes in bronchoalveolar fluid in acute COPD exacerbation before and after tiotropium bromide treatment
Conclusions: The obtained findings indicate the effect of tiotropium bromide on reduce of collagen-IV levels, especially of long term drug use. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Kulynych-Miskiv, M., Ostrovskyy, M., Miskiv, V., Savelikhina, I., Varunkiv, O., Shvets, K., Zuban, A., Korzh, N., Molodovets, O., Korzh, G. Tags: Airway pharmacology and treatment Source Type: research
Experience of clinicians on dual bronchodilator therapy in COPD (EXPAND) in Nepal
This cross-sectional, observational survey evaluated diagnosis, management trends and current perceptions and experiences of clinicians [(CLs); n=96; pulmonologist-13, physician-57, general practitioner-26] in Nepal on use of dual bronchodilator therapy in COPD management.93% of CLs were practising in urban setting for an average of 10 years and average 35% of their patients are of COPD. 61% of CLs use mMRC with (34%) or without (27%) CAT score. 92% of CLs perceived that majority of their patients had 1 (32%) or >1 (59%) exacerbation/year. 54% of CLs performed spirometry in all their patients with suspected COPD. 49% of...
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Chokhani, R., Shrestha, S. K., Bhattarai, S., Mukhopadhayay, A., Gaur, V., Gogtay, J. Tags: Airway pharmacology and treatment Source Type: research
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
